PDCD1 and non-small cell lung carcinoma: Mounting evidence shows that EGFR mutation is an important factor affecting the therapeutic efficacy of PD-1 inhibitors in NSCLC patients, and patients with EGFR mutation responded to the treatment less well than their counterparts without EGFR mutation (59–62).